

IN THE CLAIMS:

Claims 1-14 (canceled)

Claim 15. (previously amended) An immunogenic composition comprising: a CS3 peptide, said peptide selected from CS3 consisting of the amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No: 3

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (canceled)

Claim 19. (canceled)

Claim 20. (canceled)

Claim 21. (previously presented) The immunogenic composition of claim 15, wherein said composition is immunogenic against pathogenic microorganisms and neoplasms.

Claim 22. (previously presented) The immunogenic composition of claim 15, wherein said composition is immunogenic against Enterotoxogenic E. Coli.

Claim 23. (canceled)

Claim 24. (canceled)

Claim 25. (previously presented )The immunogenic composition of claim 15, wherein said composition is combined with an immunologically acceptable carrier.

Claim 26. (previously presented) The immunogenic composition of claim 25, wherein said encapsulation microspheres comprise biodegradable bio-compatible poly (DL-lactide-co-glycolide) as a bulk matrix.

Claims 27-37 (cancelled)

Claim 38-47 (cancelled)

Claim 48. (previously presented) The immunogenic composition of claim 15 wherein said peptide is a synthetic peptide.

Claim 49. (previously presented) The immunogenic composition of claim 25 wherein said immunologically acceptable carrier comprises encapsulating microspheres.

Claim 50. (currently amended) The immunogenic composition of claim 15, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1 ~~inhibiting the binding of HA residues 306-318.~~

Claim 51. (previously presented) An immunogenic composition comprising: a CS3 peptide with an amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No: 3, wherein said peptide is not a whole CS3 protein.

Claim 52. (currently amended) The immunogenic composition of claim 51, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1 ~~inhibiting the binding of HA residues 306-318.~~

Claim 53. (canceled)

Claim 54. (canceled)

Claim 55. (New) The immunogenic composition of claim 50, wherein when said peptide binds to the Class II receptor DR1, it inhibits the binding of HA residues 307-319.

Claim 56. (New) The immunogenic composition of claim 52, wherein when said peptide binds to the Class II receptor DR1, it inhibits the binding of HA residues 307-319.